Research programme: antibody therapeutics - Regeneron/Sanofi

Drug Profile

Research programme: antibody therapeutics - Regeneron/Sanofi

Alternative Names: ANG2 antibodies - Regeneron/Sanofi; Angiopoietin-2 antibodies - Regeneron/Sanofi; Anti-ANG2 antibodies - Regeneron/Sanofi; Anti-PDGF antibodies - Regeneron/Sanofi; Antibody collaboration - Regeneron/Sanofi; Therapeutic antibodies - Regeneron Pharmaceuticals/sanofi-aventis

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Class Antibodies; Antineoplastics; Bispecific antibodies; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiopoietin-2 inhibitors; CD223 antigen inhibitors; Immunomodulators; Platelet-derived growth factor receptor antagonists; Programmed cell death-1 ligand-1inhibitors; TNFRSF18 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Eye-Disorders; Unspecified

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Eye-disorders in USA (Parenteral)
  • 28 Jul 2018 No recent reports of development identified for research development in Undefined in USA (Parenteral)
  • 28 Jul 2015 Regeneron and Sanofi agree to co-promote and co-develop for the treatment of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top